Bristol Myers Squibb stock fell 3.83 percent after target cut

Published on 10/06/2026 at 13:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock faced a pipeline warning after Leerink cut its target from USD 73 to USD 59 on October 5. Q2 revenue reached USD 12.97 billion.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb stock (ISIN US1101221083) closed at USD 58.81 on the NYSE on October 5, 2026, down 3.83 percent from the previous close. The decline followed Leerink Partners' downgrade from Outperform to Market Perform and its price-target cut from USD 73 to USD 59, as Markets Insider reported on October 5, 2026.

Pipeline risk drives the downgrade

Leerink changed its view after assessing several late-stage pipeline programs, according to Markets Insider. The firm cited uncertainty around upcoming readouts for admilparant, milvexian and Cobenfy, placing future portfolio execution at the center of the debate.

The price move leaves the shares 14.3 percent below their 52-week high of USD 68.64 and above the 52-week low of USD 42.52. Trading volume reached 19,239,544 shares on October 5, compared with a three-month average of 11.2 million shares.

Quarterly numbers offer a counterweight

Bristol Myers Squibb's latest reported quarter delivered a stronger operating picture. For Q2 2026, the company reported USD 12.97 billion in revenue, up 5.7 percent year over year, and adjusted EPS of USD 2.04 versus a USD 1.60 consensus estimate, according to MarketBeat. The EPS beat was USD 0.44, while the revenue comparison shows that current growth has not removed longer-term pipeline concerns.

MarketBeat reported a Moderate Buy consensus from 25 analysts, with an average target of USD 67.06. That target lies 14.0 percent above the October 5 closing price, creating a clear gap between the broad analyst view and Leerink's more cautious USD 59 stance, according to MarketBeat.

Q3 results arrive October 29

The next scheduled checkpoint is Bristol Myers Squibb's Q3 2026 results. The company said in a release dated September 18, 2026, that it will publish the figures on October 29, 2026, followed by an 8:00 a.m. ET conference call, according to Bristol Myers Squibb. The report will test whether quarterly growth and newer medicines can offset the pipeline risks that drove the latest rating change.

Stock closes at USD 58.81

Bristol Myers Squibb stock closed at USD 58.81 on the NYSE on October 5, 2026, with a market capitalization of USD 120.1 billion and a 52-week range of USD 42.52 to USD 68.64.